Officinalisin II



Compound IDCDAMM02355
Common nameOfficinalisin II
IUPAC name2-[4-[6-hydroxy-16-[4-hydroxy-6-(hydroxymethyl)-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
Molecular formulaC50H84O23

Experimental data

Retention time4.5
Adduct[M+Na]+
Actual mz1075.53
Theoretical mz1075.53
Error0.2
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.9907

Identifiers and class information

Inchi keyTUDCHFPLNJLAIG-UHFFFAOYNA-N
SmilesOCC1OC(OCC(C)CCC2(O)OC3CC4C5CCC6CC(OC7OC(CO)C(OC8OCC(O)C(O)C8O)C(O)C7OC9OC(CO)C(O)C(O)C9O)CCC6(C)C5CCC4(C)C3C2C)C(O)C(O)C1O
SuperclassLipids and lipid-like molecules
ClassSteroids and steroid derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)19
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)29
Number of reactive functional groups (#rtvFG)5
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)1053.2
Computed dipole moment(dipole)5.076
Total solvent accessible surface area (SASA)1360.14
Hydrophobic component of SASA (FOSA)863.987
Hydrophilic component of SASA (FISA)496.155
Pie component of the SASA (PISA)0
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2859.75
Number of hydrogen bond donors (donorHB)14
Number of hydrogen bond acceptors (accptHB)37.2
Free energy of solvation of dipole (dip^2/V)0.0090108
Index of cohesive interaction in solids (ACxDN^.5/SA)0.102335
Globularity descriptor (glob)0.716362
Predicted polarizability in cubic angstroms (QPpolrz)89.672
Predicted hexadecane/gas partition coefficient (QPlogPC16)31.598
Predicted octanol/gas partition coefficient (QPlogPoct)71.855
Predicted water/gas partition coefficient (QPlogPw)57.116
Predicted octanol/water partition coefficient (QPlogPo/w)-3.257
Predicted aqueous solubility (QPlogS)-2.4
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.653
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.122
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.195
Predicted brain/blood partition coefficient (QPlogBB)-7.63
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.048
Predicted skin permeability, log Kp (QPlogKp)-7.879
PM3 calculated ionization potential (IP(ev))10.327
PM3 calculated electron affinity (EA(eV))-1.379
Number of likely metabolic reactions (#metab)13
Prediction of binding to human serum albumin (QPlogKhsa)-2.411
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)361.211
Number of nitrogen and oxygen atoms (#NandO)23
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P15692VEGFAVascular endothelial growth factor AT20761SwissTargetPrediction
P05230FGF1Acidic fibroblast growth factorT18639SwissTargetPrediction and SEA
P09038FGF2Basic fibroblast growth factorT31621SwissTargetPrediction
Q9Y251HPSEHeparanaseT47623SwissTargetPrediction
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
O15439ABCC4Multidrug resistance protein 4T39919SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T47623DI0020African trypanosomiasis[ICD-11: 1F51]Q9Y251HPSE
T47623DI0310Ocular disease[ICD-11: N.A.]Q9Y251HPSE
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR

Copyright © 2025